Gender specific associations between matrix metalloproteinases and inflammatory markers in post myocardial infarction patients

Atherosclerosis

Volumn 202, Issue 2, 2009, Pages 550-556

  Samnegård, Ann ^a,b   Hulthe, Johannes ^c   Silveira, Angela ^a   Ericsson, Carl Göran ^b   Hamsten, Anders ^a   Eriksson, Per ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Gender; Inflammation; MMP; Myocardial infarction

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CCL2 PROTEIN, HUMAN; GELATINASE B; IL6 PROTEIN, HUMAN; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MONOCYTE CHEMOTACTIC PROTEIN 1; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART INFARCTION; HUMAN; IMMUNOLOGY; MALE; METABOLISM; SEXUAL DEVELOPMENT;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHEMOKINE CCL2; CORONARY ARTERY DISEASE; FEMALE; HUMANS; INTERLEUKIN-18; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MYOCARDIAL INFARCTION; SEX CHARACTERISTICS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 61349170806     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.05.050     Document Type: Article

References (31)

1. Hansson G.K., Robertson A.-K.L., Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol Mech Dis 2006, 1:297-329.
2. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
3. Beaudeux J., Giral P., Bruckert E., Foglietti M., Chapman M. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 2004, 42:121-131.
4. Johnson J.L. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther 2007, 5:265-282.
5. Henney A., Wakeley P., Davies M., et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridisation. Proc Natl Acad Sci USA 1991, 88:8154-8158.
6. Galis Z., Sukhova G., Lark M., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493-2503.
7. Sukhova G.K., Schonbeck U., Rabkin E., et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999, 99:2503-2509.
8. Galis Z.S., Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002, 90:251-262.
9. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005, 85:1-31.
10. Whatling C., Bjork H., Gredmark S., Hamsten A., Eriksson P. Effect of macrophage differentiation and exposure to mildly oxidized LDL on the proteolytic repertoire of THP-1 monocytes. J Lipid Res 2004, 45:1768-1776.
11. Samnegard A., Silveira A., Lundman P., et al. Serum matrix metalloproteinase-3 concentration is influenced by MMP-3 1612 5A/6A promoter genotype and associated with myocardial infarction. J Intern Med 2005, 258:411-419.
12. Hulthe J., McPheat W., Samnegard A., Tornvall P., Hamsten A., Eriksson P. Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6. Atherosclerosis 2006, 188:450-454.
13. FitzGerald S.P., Lamont J.V., McConnell R.I., Benchikh E.O. Development of a high-throughput automated analyzer using biochip array technology. Clin Chem 2005, 51:1165-1176.
14. Blankenberg S., Rupprecht H.J., Poirier O., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003, 107:1579-1585.
15. Renko J., Kalela A., Jaakkola O., et al. Serum matrix metalloproteinase-9 is elevated in men with a history of myocardial infarction. Scand J Clin Lab Invest 2004, 64:255-261.
16. Silence J., Lupu F., Collen D., Lijnen H.R. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol 2001, 21:1440-1445.
17. Johnson J.L., George S.J., Newby A.C., Jackson C.L. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci USA 2005, 102:15575-15580.
18. Hochman J.S., Tamis J.E., Thompson T.D., et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. N Engl J Med 1999, 341:226-232.
19. Lagerqvist B., Safstrom K., Stahle E., Wallentin L., Swahn E. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men?. J Am Coll Cardiol 2001, 38:41-48.
20. Daly C., Clemens F., Lopez Sendon J.L., et al. Gender differences in the management and clinical outcome of stable angina. Circulation 2006, 113:490-498.
21. Lanz J.R., Pereira A.C., Martinez E., Krieger J.E. Metabolic syndrome and coronary artery disease: is there a gender specific effect?. Int J Cardiol 2006, 107:317-321.
22. Farb A., Burke A.P., Tang A.L., et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996, 93:1354-1363.
23. Virmani R., Burke A.P., Farb A. Plaque rupture and plaque erosion. Thromb Haemost 1999, 82(Suppl. 1):1-3.
24. Hellings W.E., Pasterkamp G., Verhoeven B.A.N., et al. Gender-associated differences in plaque phenotype of patients undergoing carotid endarterectomy. J Vasc Surg 2007, 45:289-296.
25. Jones C.B., Sane D.C., Herrington D.M. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003, 59:812-823.
26. Formato M., Farina M., Spirito R., et al. Evidence for a proinflammatory and proteolytic environment in plaques from endarterectomy segments of human carotid arteries. Arterioscler Thromb Vasc Biol 2004, 24:129-135.
27. Devaraj S., O'Keefe G., Jialal I. Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. J Clin Endocrinol Metab 2005, 90:4549-4554.
28. Ridker P.M., Rifai N., Clearfield M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 344:1959-1965.
29. Solheim S., Seljeflot I., Arnesen H., Eritsland J., Eikvar L. Reduced levels of TNFα In hypercholesterolemic individuals after treatment with pravastatin for 8 weeks. Atherosclerosis 2001, 157:411-415.
30. Rezaie-Majd A., Maca T., Bucek R.A., et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002, 22:1194-1199.
31. Ascer E., Bertolami M.C., Venturinelli M.L., et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 2004, 177:161-166.